Ysios Capital, a Barcelona, Spain-based biotechnology venture capital firm, held the final closing of its second fund, at €126.4m.
Ysios BioFund II Innvierte FCR, which exceeded its initial target fund size of €100m, attracted both returning investors as well as new investors. These include CDTI (Spanish Ministry of Economy) through its Innvierte program, the European Investment Fund (EIF), the European Commission through InnovFin SME Venture Capital, a financial instrument developed under the EU Framework Programme for Research and Innovation Horizon 2020; pension funds Orza and Lagun Aro; Banc Sabadell (BIDSA) and other private investors.
The fund has a strategy similar to its predecessor fund Ysios BioFund I (currently under divestment) planning to invest in biotech, medtech and diagnostic companies across Europe with a special interest in Spain. It will finance up to 15 startups and development phase companies with disruptive products, platforms or technologies that address unmet medical needs.
To date, Ysios BioFund II Innvierte has invested in five companies, including:
– Sanifit (Spain);
– Minoryx Therapeutics (Spain);
– Aelix Therapeutics (Spain);
– Prexton Therapeutics (Switzerland); and
– Aura Biosciences (U.S.).
Founded in 2008 and led by Josep Ll. Sanfeliu, Joël Jean-Mairet, Karen Wagner, Julia Salaverria and Cristina Garmendia, Ysios Capital now manages almost €200m across two funds. It has a team of 13 international professionals in both Barcelona and San Sebastian.